MedTrace Logo

Enhanced Population-based Core Surveillance of Meningococcal Invasive Infections at Participating Centers Across Canada

NCT04184336 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2022-04-11

No results posted yet for this study

Summary

Active metropolitan area surveillance for hospital admissions related to invasive infection with Neisseria meningitidis will be conducted at the 12 centers in the IMPACT network in collaboration with Public Health officials, local infection specialists and infection control practitioners during the interval from January 1, 2016 to December 31, 2022.

Conditions

  • Invasive Meningococcal Disease

Interventions

OTHER

surveillance

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Canadian Paediatric Society

    lead OTHER

Eligibility

Min Age
1 Minute
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04184336 on ClinicalTrials.gov